Navigation Links
Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
Date:11/20/2008

    PRELIMINARY TOP LINE RESULTS OF FIRST PHASE III TRIAL SHOW SIGNIFICANT
     DECREASES IN PAIN AND FATIGUE, AND IMPROVEMENT IN DAILY FUNCTION, IN
                            FIBROMYALGIA PATIENTS

PALO ALTO, Calif., and BRUSSELS, Belgium, Nov. 20 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced today positive preliminary top-line results from the first of two Phase III pivotal clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. The randomized, double-blind, placebo-controlled study achieved its primary endpoints, demonstrating that sodium oxybate significantly decreased pain and fatigue, and improved daily function, in patients with fibromyalgia.

"There is a significant unmet need in diagnosing and treating millions of patients with fibromyalgia. Potential new treatments that address the various symptoms can have a significant impact on patients' quality of life," said I. Jon Russell, M.D., Ph.D., the study's lead investigator and Associate Professor of Medicine, Division of Clinical Immunology and Rheumatology, and Director, University Clinical Research Center, University of Texas Health Science Center at San Antonio.

The 14-week study included 548 adult patients with fibromyalgia randomized to one of three treatment arms: sodium oxybate 4.5 g/night, sodium oxybate 6 g/night or placebo. The primary outcome measure, viewed by both U.S. and EU regulatory authorities as a clinically meaningful endpoint, was the proportion of patients who achieved at least 30 percent reduction in pain from baseline to endpoint based on the Pain Visual Analog Scale (VAS). In the EU it is also considered that Fibromyalgia Impact Questionnaire (FIQ) data is equally relevant. FIQ data are considered supportive data by U.S. regula
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
2. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
3. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
4. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
5. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
6. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
7. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
8. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
9. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014  Neurocrine ... that the Company will report its second quarter 2014 ... August 6, 2014.  Neurocrine will then host a live ... and provide a Company update Thursday morning, August 7, ... Time). Participants can access the live conference ...
(Date:7/29/2014)... TORONTO , July 29, ... ESAQ), an emerging pharmaceutical company exploring drug ... novel formulations and alternative dosage forms of ... its pharmaceutical development implementing its sub-micron platform technology.  ... drugs that will address indications in diabetes ...
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
Breaking Medicine Technology:Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3
(Date:7/29/2014)... The Board of Governors of the State Bar ... Connie Akridge to serve as a trustee of ... the Foundation. Akridge served as President of the State Bar ... Holland & Hart in Las Vegas, providing tailored counsel on ... and healthcare clients for more than 25 years. She regularly ...
(Date:7/29/2014)... New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. , The study finds that the majority ...
(Date:7/29/2014)... The Law Offices of Michael Cordova is ... a non-profit organization providing grief camps for kids, teens, adults, ... suffering our clients experience from the death of a loved ... organization like Stepping Stones of Hope, as they provide hope ... of Hope also includes a monthly support group and a ...
(Date:7/29/2014)... app that helps headache sufferers to record the severity ... part of a Griffith research study. , A new ... looks at coping with their triggers and is being ... Behaviorial Basis of Health program. , He has developed ... the triggers of their headaches called Learning to Cope ...
(Date:7/29/2014)... most cases of cancer is to surgically remove the ... that the surgeon may fail to extract the entire ... new technique, researchers at the University of Pennsylvania have ... entire tumor in the patient, increasing the likelihood of ... dye that accumulates in cancerous tissues much more so ...
Breaking Medicine News(10 mins):Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3
... risk of dementia according to recent research. // ,People ... risk of dementia and Alzheimer’s disease. ,DHA or docosahexaenoic ... that is required for the proper functioning of the central ... issue of the Archives or Neurology. ,According to lead ...
... An Austrian study points out that the risk of developing ... results of the study done by researchers from Medical University ... ,The study found out that marathon runners have increased chances ... .Both liver spots and moles reflect a higher risk to ...
... virus boost the cancer-killing abilities of existing cancer drugs? ... on Molecular Targets and Cancer Therapeutics, in Prague, Czech ... may lead to more effective treatment options for patients ... in which malignant (cancer) cells form in the tissues ...
... law to register all health care infrastructure in the country ... // ,"The act named as the Clinical Establishment Act ... and will register all health care institutes, infrastructure and human ... in a function entitled "Public Health Initiative: PPP model"., ...
... Hobart Hospital who are attending to babies born to ... the babies are discharged from the hospital. It is ... addictions at the hospital annually., ,The director ... Peter Dargaville, said, "We see the most severely affected ...
... that more than two thirds of the Britons fearing heart ... an ambulance. //The reluctance in calling emergency help have proved ... to be the biggest killer, often killing at least one ... ,The poll was conducted under the BHF's 'Doubt Kills' ...
Cached Medicine News:Health News:Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs 2
... Sodium Hyaluronate (1.8%) viscoelastic solution combines maximum ... Rayflo maintains a deep anterior chamber and ... is ideal for routine cataract surgery but ... requiring a viscoelastic. Combine all these properties ...
... Healon5 is a sterile, non-pyrogenic, transparent ... noninflammatory, high molecular weight (average molecular ... Healon5 contains 23 mg/mL of sodium ... units of N-acetylglucosamine and sodium glucuronate ...
... is a highly retentive, dispersive viscoelastic. ... weight, low pseudoplasticity and low surface ... and excellent tissue protection. It is ... (catalog number 8065183905) or as part ...
... planning workstation is used to plan precisely ... Planning Workstation, the surgeon can simulate the ... the patient. This enables the selection of ... material waste and procedural costs. The surgeon ...
Medicine Products: